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Prostaglandin E2 (PGE2) increased the blood pressure , heart rate and body temperature, 
when administered at the doses ofO.OOI-IO,ug into the lateral cerebral ventricle (i.c.v.) of 
the urethane-anesthetised rat. The highest dose of 10 ,ug/rat induced a strong initial 
hypotensive effect. lntravenously (i.v.) , PGE2 at the doses of 0.01-10 ,ug/rat caused a 
biphasic blood pressure response with dose-related initial decreases followed by slight 
increases in blood pressure. The heart rate and body temperature were slightly increased 
by i.v. administrations of PGE2 . The highest i.v. dose of 10 ,ug/rat initially decreased also 
the heart rate. Central pretreatment with indomethacin ( I mg/rat i.c.v.) partly antagonised 
all of the recorded central effects of PGE2 , while sodium meclofenamate (I mg/rat i.c. v.) 
abolished the hypertensive response to i.c. v. administered PGE2 but failed to significantly 
affect the PGE2-induced rises of heart rate and body temperature . The results support the 
previous suggestions that PGE2 may participate in the central cardiovascular and thermo-
regulatory contro!. The results also suggest that indomethacin and sodium meclofenamate 
antagonize the effects of exogenous prostaglandins . Since sodium meclofenamate, unlike 
indomethacin, affected preferentially the hypertensive response to centrally administered 
PGE2 , there may be differences in the sites and/or modes of action between these drugs . 
Prostagiandin E2 (PGE2) is found in the rat brain 
(Abdel-Halim et al. 1977), but its possible physio-
10gical functions in the central nervous system are 
not known. Some investigators have suggested that 
prostaglandins may be involved in the central con-
trol of the cardiovascular and thermoregulatory 
systems (Coceani 1974, Karppanen et al. 1979). 
PGE2 raised the blood pressure and heart rate of 
conscious rats upon intracerebroventricular (i.c. v.) 
administration (Hoffman & Schmid 1979). Prosta-
glandins of the E-series are also highly active hy-
perthermic agents in the brain (Milton 1976, 
Splawinski et al. 1978). However, the possible as-
sociation between the cardiovascular and thermal 
effects of centrally administered PGE2 has not been 
studied. 
In the present study increasing doses of PGE2 
were administered intravenously (i. v.) or i.c . v. to 
the urethaneanesthetised rat in order to obtain com-
plete simultaneous cumulatative dose-response 
curves for blood pressure, heart rate and body tem-
perature. Since sodium meclofenamate interferes 
with the actions of exogenous prostaglandins both 
in the peripheral tissues (Bennett et al. 1980a, b) 
and in the brain (Karppanen et al. 1979, Siren 
1981 a, b) , it seemed worthwhile to examine the 
influence of this agent on the central effects of 
PGE2 • For comparison, the effects of indometha-
cin, an equally effective inhibitor of prostagiandin 
synthesis as sodium meclofenamate (Flower 1974) , 
were also studied . 
MATERIALS AND METHODS 
Male Wistar rats (260-360 g) were used . The rats were 
accommodated to standard ambient conditions for at least 
one week before the experiments. The lights were on from 
6 a.m. to 6 p.m. and the room was completely dark during 
the remaining 12 h. The temperature was kept at 22°C and 
the relative humidity at 40 %. The rats received standard 
rat pellets (Hankkija Oy, Helsinki) and tap water ad libi-
turn. 
The rats were anesthetised with urethane (1 .5 g/kg in-
traperitoneally). The trachea was cannulated with a poly-
I A preliminary report of this work has been presented at 
the XXXII Meeting of the Scandinavian Pharmacological 
Sl.ciety (Sin~n 1981 a) . 
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Fig . 1. Time-dose-response effect of PGE, on blood pres-
sure in urethane-anesthetised rats . Increasing doses of 
PGE2 were administered i.c.v. ( ........ ) or i.v. (.-.) at 
20 min intervals. Open circles represent the vehicle i.c .v. 
controls. The initial blood pressure level (mean±SE) be-
fore commencement of the PGE2 or vehicle administra-
tions was 1I0± 10 mmHg in the control group , 113±8 
mmHg in the PGE2 i.c .v. group and 102±6 mmHg in the 
PGE2 i. v. group. The differences between the initial lev-
els of the groups are not statistically significant. The rises 
of blood pressure induced by PGE2 i.c .v. allhe doses of 
0.001-10 /1-g/rat differ significantly (p<0.05-O.00l) from 
both the control group and the PGE2 i.v . group. Vertical 
bars indicate SE. Each group comprised 6 rats. 
ethylene tube and the rats were allowed to brealhe sponla-
neously. The mean arterial blood pressure was measured 
from the left femoral artery by means of apressure trans-
ducer (Hewlett Packard 1280). The he art rate was calcu-
lated from the pulse waves by means of a rate computer 
(Hewlett Packard 8812A). The left femoral vein was can-
nulated for i.v. injections. The rats were mounted in a 
stereotaxic instrument and tilted caudally so that the body 
formed an angel of 10° with the horizontal plane. I.c.v. 
injections were performed as described in detail by Paak-
kari (1980). Briefly, an injection needle was introduced 
into the right lateral ventricle of the brain. A polyethylene 
catheter, filled with the drug or control solution to be 
infused, was attached to the needle and the desired 
amount of the solution was allowed to flow slowly by 
virtue of the hydrostatic pressure. The infusion was 
stopped by closing the upper end of the catheter. The 
proper position of the needle tip was ascertained at the 
end of each experiment by an injection of dye (Giemsa 
Solution, Merck) into the cerebral ventricle . The body 
temperature was measured rectally with a temperature 
recorder (ELLAB instruments, type TE 3, Copenhagen), 
a probe being introduced 5 cm into the rectum. A 60 W 
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heating lamp was placed 20 cm above the rat. Experi-
ments on control rats showed that this distance of the 
heating lamp was adequate to keep the body temperature 
at 36.9±0.3°C (mean ±SE) in an ambient temperature of 
2rC. 
Administration 01 drugs 
Prostagiandin E2 (PGE2), kindly supplied by Dr J. Pike of 
the Upjohn Laboratories , was dissolved in absolute eth-
anol (10 mg/mI) and stored at -20°C. Further dilutions 
were made freshly each day in 0.9% (w/v) NaCI (saline) 
for i.v. injections, and in a modified Krebs-Ringer bicar-
bonate buffer (see Karppanen et al. 1979) for i.c.v. injec-
tions . These were given in a volume of 10 /1-1 each and the 
i.v. injections in a volume of 0.15 ml each. The control 
animals received the same volume of the vehicle (buffer or 
saline solution with the corresponding concentration of 
ethanol as in the drug solution) in each case. Increasing 
doses of PGE2 were administered i.c.v. at 20 min inter-
vals in order to obtain cumulative dose-response curves. 
This interval was chosen because in the preliminary ex-
periments (PGE2 administered at 45 min intervals) the 
maximum cardiovascular effects of PGE were reached 
within 15-20 min after each i.c.v. injection. For compari-
son, the i.v. injections were also repeated at 20 min inter-
vals to make sure that the effects induced by centrally 
administered PGE2 were not due to a leakage of the drug 
into the peripheral circulation. 
Indomethacin (Orion Pharmaceutical Co., Helsinki) 
was dissolved in 0.25 N NaOH and sodium meclofena-
mate monohydrate (Parke , Davis & Co.) in saline. The 
influence of central pretreatment with indomethacin or 
sodium meclofenamate on the central effects of PGE2 was 
studied by injecting these drugs i.c.v. at a dose of I mg/rat 
20 min before commencement of the administrations of 
increasing doses of PGE2 i.c.v. The control animals re-
ceived the same volume of saline or NaOH in each case. 
The Student's t-test was used to calculate the statistical 
significance of the differences between the control and 
experimental groups. 
RESULTS 
I. Effects of prostagIandin E2 in non-pretreated 
rats 
Effect of PGE2 on blood pressure (Fig. 1). Intrace-
rebronventricular administration of PGE2 at the 
doses of 0.001-10 p,g/rat raised the blood pressure. 
The maximum pressor effect was reached 15 to 20 
min after each injection. At the highest dose of 10 
p,g/rat PGE2 i.c.v. induced an initial hypotensive 
effet which had its maximum 1-2 min after the 
injection. The initial hypotension was followed by a 
longer lasting hypertensive phase . Intravenously , 
PGE2 (0.01-10 p,g/rat) induced a biphasic blood 
pressure response with a strong dose-related initial 
decrease followed by a slight increase in blood 
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Fig. 2. Time-dose-response effect of PGE2 on heart rate 
in urethaneanesthetised rats . lncreasing doses of PGE2 
were administered i.c.v . ( ........ ) or i.v. (.-.) at 20 min 
intervals. Open circles represent the vehicle Lc. v. con-
trols. The initial heart rate level (mean±SE) before com-
mencement of the PGE2 or vehicle administrations was 
445 ± 10 beatsImin in the control group, 445±5 beatsImin 
in the PGE2 Lc .v. group and 425±10 beatsImin in the 
PGE2 i.v. group. The differences between the initiallev-
els of the groups are not statistically significant. The 
tachycardic effect of PGE2 i.c.v . at the doses ofO.OOI-1O 
p.g!rat differ significantly \p<0.054>.00 I) from both the 
control group and the PGE2 i. v. group. The rises induced 
by PGE2 i.v. at the doses ofO.l-l0 p.g!rat were significant 
at the p<0.05-O.001 level as compared to the control 
values. Vertical bars indicate SE. Each group comprised 6 
rats. 
pressure. The maximum hypotensive effeet was 
aehieved 1-2 min after eaeh i.v. injeetion. 
Effect of PGE2 on heart rate (Fig. 2) . PGE2 
indueed a substantial taehyeardie effeet, when ad-
ministered at the doses ofO.OO1-l0,ug/rat i.e.v. The 
maximum inerease in heart rate was reaehed 1(}"'20 
min after eaeh injeetion . I.v . PGE2 at the same 
doses slightly inereased the heart rate. In addition , 
at the highest i.v. dose PGE2 eaused a transient 
initial deerease in heart rate . 
Effect of PGE2 on body temperature (Fig. 3). 
PGE2 at the i.e.v. doses ofO.OOl-lO,ug/rat indueed 
a strong hyperthermie efIeet. The maximum efIeet, 
about 2SC, was reaehed with the highest dose. 
I.v . the same doses ofPGE2 only slightly raised the 
body temperature. 
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Fig . 3. Time-dose-response effect of PGE2 on body tem-
perature in urethane-anesthetised rats . Increasing doses 
of PGE2 were administered i.c.v. ( ........ ) or i.v. (.-.) 
at 20 min intervals. Open circles represent the vehicle 
i.c.v. controls . The initial body temperature level (mean 
±SE) before commencement of the PGE2 or vehicle ad-
ministrations was 36.3±0.ZOC in the control group, 
36.5±0.2°C in the PGE2 i.c .v. group and 35.0±0.3°C in 
the PGE2 i.v. group. The baseline level of the PGE2 i.v. 
group differs significantly (p<0.005-O.00l) from both the 
control and PGE2 i.c.v. groups . The rises of body tem-
perature induced by PGE2 i.c.v. (0.001-10 p.g!rat) or 
PGE2 Lv. (0.01-10 p.g!rat) are significant at the 
p<0.05-O.001 level as compared to · the control values. 
The differences between the PGE2 i.c. v. and i. v. groups 
are also significant at the p<O.054>.OOI level. Vertical 
bars indicate SE. Each group comprised 6 rats . 
11. EfJects ofindomethacin and sodium meclofena-
mate 
Centrally administered indomethaein (1 mg/rat 
i.e. v.) indueed a slight but statistieally signifieant 
inerease in heart rate (about 20 beats/rn in) but had 
no signifieant efIeet on blood pressure or body 
temperature. The same dose of sodium meclofena-
mate had no signifieant efIeet on blood pressure, 
heart rate or body temperature (see legend of Fig. 
4) . 
111. EfJects of prostaglandin E2 in indomethacin or 
sodium meclofenamate pretreated rats 
Effect of indomethacin pretreatment (Fig. 4). Cen-
tral pretreatment with indomethacin (1 mg/rat 
i.e. v.) partly antagonised the eentral hypertensive, 
taehyeardic and hyperthermie effeets of PGE2 • 
EfJects of sodium meclofenamate pretreatment 
(Fig. 4). Central pretreatment with sodium meclo-
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Fig. 4. Effect of i.c.v . administered PGE2 on blood pres-
sure, heart rate and body temperature in indomethacin or 
sodium mec10fenamate pretreated rats . Indomethacin, I 
mg/rat (.A-A), sodium mec1ofenamate, I mg/rat (e-e) 
or vechic1e (0--0) was administered i.c .v. 20 min before 
commencement of the administration of PGE2 • lncreasing 
doses of PGE2 were administered i.c.v. at 20 min inter-
vals. The maximum changes 15- 20 min after each injec-
tion are shown. The initial blood pressure, heart rate and 
body temperature levels (means±SE) were 113±8 mmHg, 
460± 10 beatsImin and 36.5±0.2°C in the control group, 
115±8 mmHg, 480± 10 beatsImin and 36.9±0.3°C in the 
indomethacin pretreated group and 112±3 mmHg, 470± 10 
beatsImin and 36.4±0.3°C in the sodium mec10fenamate 
pretreated group. The difference between the initial heart 
rate values of the indomethacin group and control group is 
significant at the p<0.05 level. Vertical bars indicate SE. 
Control and indomethacin pretreated group comprised 6 
rats and sodium mec10fenamate pretreated group 5 rats, 
except for the PGE2 doses of 1 a~d 10 Jlg/rat in experi-
mental groups (4 rats) . * p<0.05 , ** p<0.OO5 and 
*** p<O.OOl vs. control group. 
fenamate (1 mg/rat i.c. v.) wholly abolished the hy-
pertensive effect of i.c. v. administered PGE2 • The 
tachycardic response to PGE2 i.c .v. was also partly 
antagonised by sodium meclofenamate , while the 
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PGErinduced central hyperthermia was not signifi-
cantly influenced by sodium meclofenamate. 
DISCUSSION 
Intracerebroventricular administration of PGE2 at 
the doses of 0.001-10 #g/rat raised the blood pres-
sure, heart rate and body temperature of the ure-
thane-anesthetised rat. At the highest dose PGE2 
caused a brief initial decrease in blood pressure. 
Since the same doses initially strongly decreased 
and subsequently slightly increased the blood pres-
sure upon i.v. administrations, the PGErinduced 
rises of blood pressure, heart rate ·and body tem-
perature were due to an action of the drug upon the 
central nervous system rather than to a leakage into 
the peripheral circulation. In addition , PGE2 i.v. 
had only negligible effects on body temperature and 
heart rate. Moreover, the antagonism of the central 
effects of PGE2 by i.c. v. pretreatment with indo-
methacin or sodium meclofenamate further sup-
ports the suggestion that the effects of i.c. v. admin-
istered PGE2 are due to an action on the cerebral 
structures. However, the brief initial hypotensive 
effect of the highest i.c.v. dose of PGE2 was not 
significantly antagonised by centrally administered 
indomethacin or sodium meclofenamate. Since 
prostaglandins are known to cross the blood-brain 
baITier (Holmes & Horton 1968), the possibility 
cannot be excluded that, at least the hypotensive 
effect of i.c. v. administered PGE2, might be due to 
a partial leakage of the drug into the periphery. 
In agreement with the present results the i.c.v. 
administration of PGE2 at the doses of 0.05-5000 
ng/rat raised the blood press ure and heart rate of 
conscious rats (Hoffman & Schmid 1979). The hy-
perthermie effect of centrally administered PGE2 
has been previously demonstrated in many mam-
malians , including the rat (Milton 1976, Splawinski 
et al. 1978). The rises of blood pressure and heart 
rate after the administration of the smallest dose of 
PGE2 became apparent earlier than did the increase 
in body temperature. It can thus be concluded that 
the cardiovascular changes were not a consequence 
of the hyperthermia. However, the dose-response 
curve for the hyperthermie effect ofPGE2 lies with-
in about the same dose range as that for the cardio-
vascular changes so that it cannot be argued that 
PGE2 is more selective in inducing cardiovascular 
changes than a rise of the body temperature . 
The central effects of PGE2 were similar to those 
of PGF2a or the prostagiandin precursor, arachi-
donic acid (Karppanen et al. 1979, Sin!n 1982). 
PGE2 and PGF2a are both endogenously formed 
by the rat brain (Abel-Halim et al. 1977). Therefore 
the formation of PGE2 and/or PGF2a from 
arachidonic acid in the brain rnight, under some 
physiological or pathophysiological conditions, 
contribute to the central control of the cardiovascu-
lar and thermoregulatory systems. 
Sodium meclofenamate completely abolished the 
hypertensive effect but did not significantly affect 
the other effects of centraUy administered PGE2• 
Indomethacin only partly inhibited the hyperten-
sive effect of PGE2 but unlike sodium meclofena-
mate this drug was able to reduce all the centrally-
induced responses to PGE2• In agreement with the 
present results sodium meclofenamate proved to be 
more potent in inhibiting the hypertensive than the 
tachycardic or hyperthermic effects of arachidonic 
acid (Siren 1982), while indomethacin affected 
equally the cardiovascular and thermal responses 
to i.c.v. administered arachidonic acid (Siren & 
Karppanen 1981). Furthermore, the central hypo-
tensive effect of prostacyclin was antagonised by 
central pretreatment with sodium meclofenamate 
but not with indomethacin (Siren 1981 b). Hence 
the present findings lend further support to our 
previous suggestion (Karppanen et al. 1979) that 
there might be differences in the modes and/or sites 
of action between sodium meclofenamate and indo-
methacin. 
The mechanism by wh ich indomethacin and sodi-
um meclofenamate inhibit the responses to central-
ly administered prostaglandins is not known. How-
ever, in agreement with the present results an an-
tagonism of the effects of exogenous prostaglandins 
by indomethacin and fenamates has also been re-
ported in the alimentary muscle of the guinea-pig 
and rat (Bennett et al. 1980a, b, Lembeck & Juan 
1974). The blockade of prostagiandin receptors by 
indomethacin and sodium meclofenamate might ex-
plain the inhibition of the effects of exogenous pros-
taglandins by these drugs. However, both indo-
methacin and fenamates effectively inhibit the syn-
thesis of prostaglandins (Flower 1974). Due to the 
decreased synthesis of endogenous prostaglandins 
the total amount of these agents, endogenous plus 
exogenous, present at the receptors after the ad-
ministration of exogenous prostaglandins, may be 
decreased. This might explain, at least partly, the 
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dirninished effects of prostaglandins after the treat-
ment with the inhibitors of prostagiandin synthesis . 
Therefore the effects of indomethacin and sodium 
meclofenamate might be due to both the inhibition 
of the endogenous synthesis of prostaglandins and 
the blockade of prostagiandin receptors. 
I thank Dr John Pike of the Upjohn Laboratories for the 
most generous supply of PGE2 . 
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